JP2017524031A - ガンマデルタｔ細胞およびその使用 - Google Patents

ガンマデルタｔ細胞およびその使用 Download PDF

Info

Publication number
JP2017524031A
JP2017524031A JP2017521620A JP2017521620A JP2017524031A JP 2017524031 A JP2017524031 A JP 2017524031A JP 2017521620 A JP2017521620 A JP 2017521620A JP 2017521620 A JP2017521620 A JP 2017521620A JP 2017524031 A JP2017524031 A JP 2017524031A
Authority
JP
Japan
Prior art keywords
cells
gamma delta
cell
subject
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017521620A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017524031A5 (enExample
Inventor
マイケル リーク
マイケル リーク
アデーレ ハンニガン
アデーレ ハンニガン
Original Assignee
ティーシー バイオファーム リミテッド
ティーシー バイオファーム リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201412175A external-priority patent/GB201412175D0/en
Priority claimed from GB201415379A external-priority patent/GB201415379D0/en
Priority claimed from GBGB1506423.1A external-priority patent/GB201506423D0/en
Application filed by ティーシー バイオファーム リミテッド, ティーシー バイオファーム リミテッド filed Critical ティーシー バイオファーム リミテッド
Publication of JP2017524031A publication Critical patent/JP2017524031A/ja
Publication of JP2017524031A5 publication Critical patent/JP2017524031A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/43—Protozoan antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/44—Fungal antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2017521620A 2014-07-09 2015-07-08 ガンマデルタｔ細胞およびその使用 Pending JP2017524031A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB201412175A GB201412175D0 (en) 2014-07-09 2014-07-09 Gamma T cells and uses thereof
GB1412175.0 2014-07-09
GB1415379.5 2014-08-29
GB201415379A GB201415379D0 (en) 2014-08-29 2014-08-29 Gamma T cells and uses thereof
GBGB1506423.1A GB201506423D0 (en) 2015-04-15 2015-04-15 Gamma delta T cells and uses thereof
GB1506423.1 2015-04-15
PCT/GB2015/051985 WO2016005752A1 (en) 2014-07-09 2015-07-08 Gamma delta t cells and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020115432A Division JP2020172522A (ja) 2014-07-09 2020-07-03 ガンマデルタｔ細胞およびその使用

Publications (2)

Publication Number Publication Date
JP2017524031A true JP2017524031A (ja) 2017-08-24
JP2017524031A5 JP2017524031A5 (enExample) 2018-08-16

Family

ID=53776892

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017521620A Pending JP2017524031A (ja) 2014-07-09 2015-07-08 ガンマデルタｔ細胞およびその使用
JP2020115432A Pending JP2020172522A (ja) 2014-07-09 2020-07-03 ガンマデルタｔ細胞およびその使用
JP2023088259A Pending JP2023123437A (ja) 2014-07-09 2023-05-29 ガンマデルタｔ細胞およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020115432A Pending JP2020172522A (ja) 2014-07-09 2020-07-03 ガンマデルタｔ細胞およびその使用
JP2023088259A Pending JP2023123437A (ja) 2014-07-09 2023-05-29 ガンマデルタｔ細胞およびその使用

Country Status (12)

Country Link
US (2) US20170196910A1 (enExample)
EP (1) EP3167050A1 (enExample)
JP (3) JP2017524031A (enExample)
KR (1) KR20170045205A (enExample)
CN (1) CN107075480A (enExample)
AU (1) AU2015287456A1 (enExample)
BR (1) BR112017000464A2 (enExample)
CA (1) CA2954546A1 (enExample)
EA (1) EA201790010A1 (enExample)
IL (1) IL249970B (enExample)
SG (1) SG11201700134PA (enExample)
WO (1) WO2016005752A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022513328A (ja) * 2018-09-27 2022-02-07 フォスフォガム， インコーポレイテッド 同種異系のガンマ／デルタｔ細胞の増殖および使用のための方法および組成物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
CN107106578B (zh) * 2014-08-12 2020-12-25 香港大学 治疗厄泼斯坦-巴尔病毒相关疾病的双膦酸盐化合物和γδT细胞-介导的疗法
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
US20180028566A1 (en) * 2016-07-29 2018-02-01 New York University Gamma delta t cells as a target for treatment of solid tumors
US20200172864A1 (en) * 2016-09-26 2020-06-04 Tessa Therapeutics Ltd. T Cell Expansion Method
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
US10519236B2 (en) 2018-01-23 2019-12-31 New York University Antibodies specific to delta 1 chain of T cell receptor
BR112021006254A2 (pt) 2018-10-01 2021-07-27 Adicet Bio, Inc. composições e métodos relativos a células t¿d engenheiradas e não engenheiradas para tratamento de tumores sólidos
JP7687952B2 (ja) 2018-10-01 2025-06-03 アディセット セラピューティクス， インク． 血液腫瘍を治療するための遺伝子操作しているγδ－Ｔ細胞及び遺伝子操作していないγδ－Ｔ細胞に関する組成物及び方法
WO2020154548A2 (en) 2019-01-23 2020-07-30 New York University Antibodies specific to delta 1 chain of t cell receptor
WO2021016652A1 (en) * 2019-07-29 2021-02-04 The University Of Melbourne METHODS AND COMPOSITIONS FOR MONITORING, TREATING AND PREVENTING CMV INFECTION OR GRAFT REJECTION USING γδ T-CELLS
CN114555785B (zh) * 2019-10-17 2024-12-06 香港大学 制备v-t细胞衍生的外泌体以治疗epstein-barr病毒相关癌症的方法
WO2021178890A1 (en) 2020-03-06 2021-09-10 Sorrento Therapeutics, Inc. Innate immunity killer cells targeting psma positive tumor cells
EP4183871A1 (en) 2021-11-23 2023-05-24 Université d'Aix-Marseille Process for preparing a composition comprising a combined cell population
KR20230105166A (ko) * 2022-01-03 2023-07-11 주식회사 이뮤노맥스 감마-델타 t 세포의 증식 배양 방법
MX2024010047A (es) 2022-02-16 2024-08-26 Priothera Sas Metodos de tratamiento con celulas car en combinacion con moduladores del receptor s1p.
DE102022132084B4 (de) 2022-12-02 2024-08-22 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
DE102022132082B4 (de) 2022-12-02 2024-08-08 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Verfahren zur Herstellung von genetisch transfizierten und mit Nanopartikeln und/oder einem zytotoxischen Stoff beladenen immunokompetenten Zellen sowie immunokompetente Zellen und medizinische Zusammensetzung.
DE102022132083B4 (de) 2022-12-02 2024-08-22 Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür
WO2025046256A1 (en) 2023-08-31 2025-03-06 Universite D'aix-Marseille Process for preparing a composition comprising a combined cell population

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535002A (ja) * 1999-01-28 2002-10-22 パルメット ヘルス アライアンス，デー／ビー／エー パルメット リッチランド メモリアル ホスピタル インビトロ活性化ガンマデルタリンパ球
JP2003529363A (ja) * 2000-04-03 2003-10-07 ヘモソル インコーポレーテッド ＴｃＲガンマデルタＴ細胞の産生
JP2008509683A (ja) * 2004-08-19 2008-04-03 ユニバーシティ オブ ベルン 抗原提示ヒトγδＴ細胞の調製及び免疫療法における使用
JPWO2008152822A1 (ja) * 2007-06-15 2010-08-26 株式会社メディネット 医薬

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2250480T3 (es) 2000-09-11 2006-04-16 Chiron Corporation Derivados de quinolinona como inhibidores de tirosina quinasa.
JPWO2006006720A1 (ja) 2004-07-13 2008-05-01 株式会社メディネット γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤
ES2350895T3 (es) * 2004-08-19 2011-01-28 University College Cardiff Consultants Limited Preparación de células t gamma delta humanas presentadoras de antígeno y su uso en inmunoterapia.
ES2391573T3 (es) 2005-09-08 2012-11-27 Medinet Co., Ltd. Método para el tratamiento de activación de una célula presentadora de antígeno

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535002A (ja) * 1999-01-28 2002-10-22 パルメット ヘルス アライアンス，デー／ビー／エー パルメット リッチランド メモリアル ホスピタル インビトロ活性化ガンマデルタリンパ球
JP2003529363A (ja) * 2000-04-03 2003-10-07 ヘモソル インコーポレーテッド ＴｃＲガンマデルタＴ細胞の産生
JP2008509683A (ja) * 2004-08-19 2008-04-03 ユニバーシティ オブ ベルン 抗原提示ヒトγδＴ細胞の調製及び免疫療法における使用
JPWO2008152822A1 (ja) * 2007-06-15 2010-08-26 株式会社メディネット 医薬

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022513328A (ja) * 2018-09-27 2022-02-07 フォスフォガム， インコーポレイテッド 同種異系のガンマ／デルタｔ細胞の増殖および使用のための方法および組成物

Also Published As

Publication number Publication date
JP2020172522A (ja) 2020-10-22
IL249970B (en) 2019-11-28
JP2023123437A (ja) 2023-09-05
KR20170045205A (ko) 2017-04-26
AU2015287456A1 (en) 2017-02-02
SG11201700134PA (en) 2017-02-27
CN107075480A (zh) 2017-08-18
WO2016005752A1 (en) 2016-01-14
CA2954546A1 (en) 2016-01-14
EP3167050A1 (en) 2017-05-17
EA201790010A1 (ru) 2017-05-31
BR112017000464A2 (pt) 2017-11-07
US20170196910A1 (en) 2017-07-13
IL249970A0 (en) 2017-03-30
US20210030794A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
JP2023123437A (ja) ガンマデルタｔ細胞およびその使用
JP6995624B2 (ja) 修正ガンマデルタｔ細胞およびその使用
JP7451468B2 (ja) 非造血組織常在性γδ Ｔ細胞の増幅および該細胞の使用
Wu et al. Human γδT-cell subsets and their involvement in tumor immunity
JP7258364B2 (ja) がんおよび関連悪性腫瘍の治療のためのγδＴ細胞を活性化、修飾、および増殖させる方法
Li et al. MART-1–specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro
JP2025092558A (ja) 養子細胞療法のための改良型細胞培養方法
JP5792622B2 (ja) ナチュラルキラー細胞の製造方法
Spel et al. Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma
US20160208216A1 (en) Methods of cell culture for adoptive cell therapy
TW201729818A (zh) 製備用於ｔ細胞治療之ｔ細胞的方法
CN113766919B (zh) 制造抗bcma car t细胞
CN104321425A (zh) 用于诱导和扩增源自外周血单个核细胞的自然杀伤细胞的方法
CN107002039A (zh) 使用t细胞用于培养自然杀伤细胞的方法
US11473059B2 (en) Method for enrichment and expansion of virus antigen-specific T cells
JP2017061558A (ja) Ｔｈ１特性と細胞溶解性を発現する細胞
CA3107515A1 (en) Method for tumor treatment with immune effector cells
TW202130807A (zh) 具有ｃｄ４５ｒａ⁺及ｃｃｒ７⁺之細胞表面標誌的t細胞之製造方法
Zhou et al. Characterization of T-cell memory phenotype after in vitro expansion of tumor-infiltrating lymphocytes from melanoma patients
Wesch et al. OPEN ACCESS EDITED BY
WO2025095114A1 (ja) 改善された白血球の製造方法
Burocchi Modulation of regulatory T cell suppression in tumors through OX40
EA043265B1 (ru) Модифицированные гамма-дельта-t-клетки и их применение

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191225

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200303